Gabapentin Market Analysis

  • Report ID: 5130
  • Published Date: May 09, 2025
  • Report Format: PDF, PPT

Gabapentin Market Segmentation:

Distribution Channel 

The hospital pharmacy segment is anticipated to account for 45% share of the global gabapentin market during the projected period. The hospital pharmacies also have exposure to patients' medical records which leads to high accuracy in medication provision. Besides, the growing demand for advanced healthcare infrastructure, especially in developing countries along with high investment in new technologies and the healthcare sector is expected to influence the segment growth in the upcoming times. Given the risk of misuse, most medicines are provided by hospitals or the healthcare industry. According to a US national survey, 6.6% of persons reported misusing gabapentin at some point in their lives, with therapeutic and non-therapeutic uses split fairly evenly.

Dosage Form 

The capsule segment in the gabapentin market is predicted to witness the largest revenue of 50 % by the end of 2035. The gabapentin medication is available in the market in various forms but the most popular and demanding form is the capsule form, owing to its easy availability, ease of administration, and correct dosing. One of the significant advantages of capsules is that they are easy to swallow which means old people or kids can take them easily and most doctors prescribe capsules over other forms owing to their huge properties. 

Our in-depth analysis of the global gabapentin market includes the following segments:

 

     Dosage Form

  • Tablet

  • Capsule

  • Oral Solution

 

     Type

  • Generic

  • Branded

 

 

     Application

  • Neuropathic Pain

  •  Epilepsy

  • Restless Legs

  • Syndrome

  • Others

 

     Distribution Channel

  • Retail Pharmacy

  • Hospital Pharmacy

  • Online Pharmacy

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of gabapentin is evaluated at USD 2.69 billion.

The global gabapentin market size was worth over USD 2.56 billion in 2025 and is poised to grow at a CAGR of more than 5.6%, reaching USD 4.41 billion revenue by 2035.

The North America gabapentin market is expected to achieve a 35% share by 2035, driven by the growing prevalence of chronic pain conditions.

Key players in the market include Sun Pharmaceutical Industries Ltd., Ascend Laboratories, LLC Apotex Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma., Amneal Pharmaceuticals LLC., Cipla USA, Inc., BP Pharmaceuticals Laboratories Company, Assertio Holdings, Inc., Arbor Pharmaceuticals, Inc., Pfizer Inc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos